This latter pitch burnt us twice in the mid-2000s: Ivrea and Proprius both had inherited ongoing Phase 2s, both of which readout as completely uninterpretable due to protocol issues among other confounding variables.

FORBES: Lessons Learned: Reflections On Early Stage Biotech Venture Investing